Welcome to the Wallace-Kelsey Research Foundation

Hamish Wallace

Hamish Wallace

Our Clinical Director is Hamish Wallace MD, a paediatric oncologist working at the Royal Hospital for Sick Children, Edinburgh. He is also a Professor at the University of Edinburgh.

Listen to a recent radio interview, or watch a recent TV interview

Tom Kelsey

Tom Kelsey

Our Scientific Director is Tom Kelsey PhD, a Senior Lecturer at the School of Computer Science of the University of St Andrews.

What We Do

The Wallace-Kelsey Research Foundation Ltd. is a UK charity (registration number 1116920) and a UK Limited Company (registration number 05591916).

We undertake and sponsor multidisciplinary and collaborative research projects aimed at improving the quality of life for childhood cancer survivors. Our main area of interest is reproduction - it is well known that chemo- and radiotherapies adversely affect reproductive capabilities, our aim is to quantify and mitigate these effects.

Featured Publication

image 3

Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation

We have shown that the Edinburgh selection criteria predict which young female patients with cancer are more likely to develop premature ovarian insufficiency and are therefore most likely to benefit from ovarian tissue cryopreservation. The procedure is invasive, requiring surgery, and the success rate in terms of future livebirths remains unknown. A minority of girls and young women with cancer are at high risk of premature ovarian insufficiency and, because this approach remains experimental, it is necessary to limit ovarian tissue cryopreservation to those patients at high risk of premature ovarian insufficiency. Future research should focus on the development of this new and experimental service for girls and young women with cancer who are at highest risk of premature ovarian insufficiency, but who have a realistic chance of survival. The full paper can be downloaded from The Lancet Oncology.